ClinicalTrials.gg
CompletedNCT05567393Updated Sep 14, 2023Results posted

A Study of TAK-951 in Healthy Adults

A Phase 1 interventional study of TAK-951 Placebo and TAK-951 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Mar 2019, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study of TAK-951 for people with symptoms of nausea and vomiting. The main aims of this study in healthy adults are as follows:

  • To check for side effects from TAK-951 when given at a slow and fast infusion rate.
  • To learn how much TAK-951 participants can receive without getting side effects from it.
  • To check how much TAK-951 stays in the blood over time to work out the best dose.

Participants will receive a single infusion of either TAK-951 or placebo. In this study, a placebo looks like TAK-951 but does not have any medicine in it. Participants will receive either a low dose or high dose of TAK-951. The infusion will take from 1-3 hours.

Participants will stay in the study clinic for about 4 days to receive the study medicine (TAK-951 or placebo) and check for side effects. They will have follow-up visits at the clinic about 2 weeks and 4 weeks after treatment.

Read the detailed description

The drug being tested in this study is called TAK-951. The study evaluated the safety, tolerability and pharmacokinetics (PK) of TAK-951 in healthy participants.

The study enrolled 128 healthy participants and consisted of 2 parts: Single-rising Dose (SRD) part (13 cohorts) of sequential panel design, and Multiple-rising Dose (MRD) part (5 cohorts) of sequential panel design. Participants in each cohort were randomized to receive treatment with TAK-951 or matching placebo using SC injection, once daily on Day 1 (for SRD part) and twice daily (BID) on Days 1 through 5 (for MRD part) following a minimum fast of 8 hours.

This single center trial was conducted in the United States. The overall time to participate in this study was approximately 155 days.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a (BMI) ≥18 and ≤30.0 (kg/m\^2) at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  1. The participant has a positive test result for surface antigen, virus antibody, or human immunodeficiency antibody/antigen, at the Screening Visit. Note: Participants with positive hepatitis B virus or hepatitis C virus serology may be enrolled if quantitative polymerase chain reaction for hepatitis B virus or hepatitis C virus ribonucleic acid is negative.
  2. The participant had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks before the Screening Visit.
  3. Heavy consumption of alcohol within 3 months before screening (>7 drinks/week for women, >14 drinks/week for men, where 1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) or use of soft drugs (such as marijuana) within 3 months before screening, or hard drugs (such as cocaine and phencyclidine) within 1 year before Screening.
  4. The participant has used nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 28 days before check-in (Day -1) or cotinine test is positive at Screening or Day -1.
  5. The participant has had 3 incidences of vasovagal syncope within the last 5 years.
  6. The participant has Brugada syndrome (right bundle branch block [RBBB] pattern with ST-elevation in leads V1-V3).
  7. The participant has an average semirecumbent systolic blood pressure \<90 millimeters of mercury (mm Hg) or diastolic blood pressure \<60 mm Hg at Screening or admission.
  8. The participant has an average heart rate (HR) \<60 or >100 beats per minute (bpm) [at Screening, at Day -1, or at predose]; athletic participants with an average HR \<60 bpm can be enrolled only with medical monitor approval.
  9. The participant has orthostatic hypotension defined as a decrease in systolic blood pressure ≥20 mm Hg or a decrease in diastolic blood pressure ≥10 mm Hg after 2 minutes of standing when compared with blood pressure from the sitting position at Screening, and at Day -1. Participants with postural orthostatic tachycardia, defined as HR >120 bpm standing, will also be excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Placebo comparator
    Part 1 (SRD): Pooled Placebo

    TAK-951 placebo-matching, single dose, subcutaneous (SC) injection, on Day 1 in fasted healthy participants in the single-rising dose (SRD) period.

    Drug: TAK-951 Placebo

  • Experimental
    Part 1 (SRD): Cohort 2: TAK-951 Dose 1

    TAK-951 Dose 1, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 1: TAK-951 Dose 2

    TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 15: TAK-951 Dose 2

    TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 3: TAK-951 Dose 3

    TAK-951 Dose 3, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 4: TAK-951 Dose 4

    TAK-951 Dose 4, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 5: TAK-951 Dose 5

    TAK-951 Dose 5, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 6: TAK-951 Dose 6

    TAK-951 Dose 6, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 13: TAK-951 Dose 7

    TAK-951 Dose 7, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 14: TAK-951 Dose 8

    TAK-951 Dose 8, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 16: TAK-951 Dose 9

    TAK-951 Dose 9, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 17: TAK-951 Dose 10

    TAK-951 Dose 10, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Experimental
    Part 1 (SRD): Cohort 18: TAK-951 Dose 11

    TAK-951 Dose 11, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.

    Drug: TAK-951

  • Placebo comparator
    Part 3 (MRD): Pooled Placebo

    TAK-951 placebo-matching, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the multiple-rising dose (MRD) period.

    Drug: TAK-951 Placebo

  • Experimental
    Part 3 (MRD): Cohort 10: TAK-951 Dose 1A

    TAK-951 Dose 1A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.

    Drug: TAK-951

  • Experimental
    Part 3 (MRD): Cohort 11: TAK-951 Dose 2A

    TAK-951 Dose 2A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.

    Drug: TAK-951

  • Experimental
    Part 3 (MRD): Cohort 12: TAK-951 Dose 3A

    TAK-951 Dose 3A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.

    Drug: TAK-951

  • Experimental
    Part 3 (MRD): Cohort 20: TAK-951 Dose 4A

    TAK-951 Dose 4A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.

    Drug: TAK-951

Interventions

  • DrugTAK-951 Placebo

    TAK-951 placebo-matching SC injection

  • TAK-951 SC injection

06

What researchers measure

Primary outcomes

  1. Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings

    Physical examination included the examination of the abdomen; extremities; head, eyes, ears, nose (HEENT); neurological; skin and mucosae; thorax.

    Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)

  2. Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Vital Signs Parameters

    The criteria for markedly abnormal values of vital signs' parameters were: Pulse Rate (beats/minute) \<50 and \>120; Systolic Blood Pressure \[millimeters of mercury (mmHg)\] \<85 and \>180; Diastolic Blood Pressure (mmHg) \<50 and \>110; Temperature \[degrees Celsius (C)\] \<35.6 and \>37.7. Only categories with atleast one participant with events are reported.

    Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)

  3. Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters

    The criteria for markedly abnormal values of 12-lead ECG parameters were: ECG Mean Heart Rate (beats/min) \<50 beats per minute and \>120 beats per minute; PR Interval, Aggregate \[milliseconds (msec)\] \<=80 msec and \>=200 msec; QRS Duration, Aggregate (msec) \<=80 msec and \>=120 msec; QT Interval with Fridericia Correction Method (QTcF) Interval, Aggregate (msec) \>=500 msec or \>=30 msec change from Baseline and \>=450 msec. Only categories with atleast one participant with event are reported.

    Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)

  4. Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Laboratory Parameters

    The laboratory parameters of chemistry, and hematology were assessed. Clinical laboratory tests included serum chemistry, hematology, and urinalysis. MAV criteria: Alanine aminotransferase(U/L) \>3xupper limit of normal(ULN); Albumin\<2.5g/dL,\<25g/L; Alkaline phosphatase (U/L)\>3 x ULN; Aspartate aminotransferase (U/L)\>3 x ULN; Bilirubin\>1.5mg/dL, \>34.2 µmol/L; Calcium\<8.0 mg/dL,LLN-\<2.0mmol/L, \>1.0mmol/L; Carbon dioxide \<8.0 (mmol/L); Chloride\<75 mmol/L,\>126 mmol/L; Creatinine\>177µmol/L; Gamma glutamyl transferase (U/L)\>2.0 mg/dL, \>3.0 x ULN; Glucose\<3 mmol/L,\>10 mmol/L; Potassium\<3.0 mmol/L \>5.5 mmol/L; Protein(g/L)\<0.8 x LLN \>1.2 x ULN; Sodium\<130mmol/L \>150mmol/L; Urea nitrogen \>10.7; Erythrocytes 10\^12erythrocytes/L) \<0.8 x LLN,\>1.2 x ULN; Hematocrit(%) \<0.8 x LLN,\>1.2xULN; Hemoglobin(g/L)\<0.8 x LLN, \>1.2 x ULN; Leukocytes(10\^9 leukocytes/L)\<0.5 x LLN \>1.5 x ULN; platelets(10\^9 platelets/L)\<75-\>600. Only categories with atleast one participant with event are reported.

    Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)

  5. Parts 1 and 3: Percentage of Participants With Treatment-Emergent Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug.

    Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)

  6. Parts 1 and 3: Percentage of Participants With Positive Immunogenicity (ADA) Status

    Time frame: From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)

Secondary outcomes

  1. Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-951

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Part 1

  2. Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951

    Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Part 1

  3. Part 3: Cmax: Maximum Observed Plasma Concentration for TAK-951 on Day 1

    Time frame: Pre-dose and at multiple time points (up to 24 hours) post-dose on Day 1 in Part 3

  4. Part 3: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval Tau (τ), From Time of First Daily Dose to 8 Hours for TAK-951 on Day 1

    Time frame: Pre-dose and at multiple time points (up to 24 hours) post-dose on Day 1 in Part 3

07

Results

Posted Sep 14, 2023

Participant flow

Participants took part in the study at 1 investigative site in the United States from 07 March 2019 to 02 November 2020.

Participant flow — Overall Study
MilestonePart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Started2466666666666686666
Completed2466666666666676666
Not completed000000000000010000
Withdrew: Voluntary withdrawal000000000000010000

Outcome measures

PrimaryParts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings

Physical examination included the examination of the abdomen; extremities; head, eyes, ears, nose (HEENT); neurological; skin and mucosae; thorax.

Time frame:
From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Reported as:
Number · percentage of participants
Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings
percentage of participantsPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings000000000000000000
PrimaryParts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Vital Signs Parameters

The criteria for markedly abnormal values of vital signs' parameters were: Pulse Rate (beats/minute) \<50 and \>120; Systolic Blood Pressure \[millimeters of mercury (mmHg)\] \<85 and \>180; Diastolic Blood Pressure (mmHg) \<50 and \>110; Temperature \[degrees Celsius (C)\] \<35.6 and \>37.7. Only categories with atleast one participant with events are reported.

Time frame:
From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Reported as:
Number · percentage of participants
Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Vital Signs Parameters
percentage of participantsPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Diastolic Blood Pressure (mmHg) <50000000016.716.733.316.716.716.70016.700
Pulse Rate (beats/minute) <508.316.7016.716.716.7000000050.050.050.0033.3
Pulse Rate (beats/minute) >12000000033.3016.716.750.050.016.70050.016.716.7
Systolic Blood Pressure (mmHg) <850000000016.733.316.716.7012.5033.300
Temperature (C) <35.64.233.316.7016.716.716.70016.70016.725.033.316.716.716.7
PrimaryParts 1 and 3: Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters

The criteria for markedly abnormal values of 12-lead ECG parameters were: ECG Mean Heart Rate (beats/min) \<50 beats per minute and \>120 beats per minute; PR Interval, Aggregate \[milliseconds (msec)\] \<=80 msec and \>=200 msec; QRS Duration, Aggregate (msec) \<=80 msec and \>=120 msec; QT Interval with Fridericia Correction Method (QTcF) Interval, Aggregate (msec) \>=500 msec or \>=30 msec change from Baseline and \>=450 msec. Only categories with atleast one participant with event are reported.

Time frame:
From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Reported as:
Number · percentage of participants
Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters
percentage of participantsPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
ECG Mean Heart Rate (beats/minute) <508.30016.716.733.3016.716.7016.716.7037.5033.3016.7
PR Interval, Aggregate (msec) >=2004.20016.7000016.700016.700000
QRS Duration, Aggregate (msec) <=8020.816.716.716.716.7033.316.7016.716.716.716.70033.316.716.7
PrimaryParts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Laboratory Parameters

The laboratory parameters of chemistry, and hematology were assessed. Clinical laboratory tests included serum chemistry, hematology, and urinalysis. MAV criteria: Alanine aminotransferase(U/L) \>3xupper limit of normal(ULN); Albumin\<2.5g/dL,\<25g/L; Alkaline phosphatase (U/L)\>3 x ULN; Aspartate aminotransferase (U/L)\>3 x ULN; Bilirubin\>1.5mg/dL, \>34.2 µmol/L; Calcium\<8.0 mg/dL,LLN-\<2.0mmol/L, \>1.0mmol/L; Carbon dioxide \<8.0 (mmol/L); Chloride\<75 mmol/L,\>126 mmol/L; Creatinine\>177µmol/L; Gamma glutamyl transferase (U/L)\>2.0 mg/dL, \>3.0 x ULN; Glucose\<3 mmol/L,\>10 mmol/L; Potassium\<3.0 mmol/L \>5.5 mmol/L; Protein(g/L)\<0.8 x LLN \>1.2 x ULN; Sodium\<130mmol/L \>150mmol/L; Urea nitrogen \>10.7; Erythrocytes 10\^12erythrocytes/L) \<0.8 x LLN,\>1.2 x ULN; Hematocrit(%) \<0.8 x LLN,\>1.2xULN; Hemoglobin(g/L)\<0.8 x LLN, \>1.2 x ULN; Leukocytes(10\^9 leukocytes/L)\<0.5 x LLN \>1.5 x ULN; platelets(10\^9 platelets/L)\<75-\>600. Only categories with atleast one participant with event are reported.

Time frame:
From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Reported as:
Number · percentage of participants
Parts 1 and 3: Percentage of Participants With Markedly Abnormal Values of Laboratory Parameters
percentage of participantsPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Calcium(mmol/L):Corrected Serum Calcium <LLN 8.0mg/dL;<LLN 2.0mmol/L;Ionized calcium<LLN 1.0mmol/L0016.7000000016.70000016.70
Glucose (mmol/L) >100000000000000016.7000
Urea Nitrogen (mmol/L) >10.7000000000000012.50000
PrimaryParts 1 and 3: Percentage of Participants With Treatment-Emergent Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event which occurred on or after the first dose of study drug and no more than 30 days after the last dose of study drug.

Time frame:
From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Reported as:
Number · percentage of participants
Parts 1 and 3: Percentage of Participants With Treatment-Emergent Adverse Events
percentage of participantsPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Parts 1 and 3: Percentage of Participants With Treatment-Emergent Adverse Events16.716.716.716.716.716.733.350.050.083.366.783.333.337.516.783.366.783.3
PrimaryParts 1 and 3: Percentage of Participants With Positive Immunogenicity (ADA) Status
Time frame:
From the first dose of study drug up to follow-up or early termination (Up to approximately 32 days)
Reported as:
Number · percentage of participants
Parts 1 and 3: Percentage of Participants With Positive Immunogenicity (ADA) Status
percentage of participantsPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Parts 1 and 3: Percentage of Participants With Positive Immunogenicity (ADA) Status00000000000000016.700
SecondaryPart 1: Cmax: Maximum Observed Plasma Concentration for TAK-951
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Part 1
Reported as:
Geometric mean · picograms per milliliters (pg/mL)
Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-951
picograms per milliliters (pg/mL)Part 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11
Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-951177 ± 22.3213 ± 35.4420 ± 14.4383 ± 20.0717 ± 29.02070 ± 24.73010 ± 38.44230 ± 32.48920 ± 41.78540 ± 23.627900 ± 19.354300 ± 14.1
SecondaryPart 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
Time frame:
Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose in Part 1
Reported as:
Geometric mean · picograms*hour per milliliters(pg*hr/mL)
Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
picograms*hour per milliliters(pg*hr/mL)Part 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11
Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951813 ± 14.6—1960 ± 8.50—3920 ± 12.39230 ± 25.715300 ± 14.021700 ± 34.446700 ± 23.350700 ± 25.7140000 ± 17.8340000 ± 20.8
SecondaryPart 3: Cmax: Maximum Observed Plasma Concentration for TAK-951 on Day 1
Time frame:
Pre-dose and at multiple time points (up to 24 hours) post-dose on Day 1 in Part 3
Reported as:
Geometric mean · pg/mL
Part 3: Cmax: Maximum Observed Plasma Concentration for TAK-951 on Day 1
pg/mLPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Part 3: Cmax: Maximum Observed Plasma Concentration for TAK-951 on Day 11260 ± 27.16010 ± 18.222400 ± 25.833700 ± 24.6
SecondaryPart 3: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval Tau (τ), From Time of First Daily Dose to 8 Hours for TAK-951 on Day 1
Time frame:
Pre-dose and at multiple time points (up to 24 hours) post-dose on Day 1 in Part 3
Reported as:
Geometric mean · pg*hr/mL
Part 3: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval Tau (τ), From Time of First Daily Dose to 8 Hours for TAK-951 on Day 1
pg*hr/mLPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Part 3: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval Tau (τ), From Time of First Daily Dose to 8 Hours for TAK-951 on Day 15420 ± 25.225000 ± 15.998100 ± 22.8152000 ± 29.4

Adverse events

Collected over From first dose of study drug and up to 30 days post last dose (Parts 1 and 3: Up to approximately 32 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 (SRD): Pooled Placebo0/24 (0%)0/24 (0%)0/24 (0%)
Part 1 (SRD): Cohort 2: TAK-951 Dose 10/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SRD): Cohort 1: TAK-951 Dose 20/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SRD): Cohort 15: TAK-951 Dose 20/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SRD): Cohort 3: TAK-951 Dose 30/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SRD): Cohort 4: TAK-951 Dose 40/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SRD): Cohort 5: TAK-951 Dose 50/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1 (SRD): Cohort 6: TAK-951 Dose 60/6 (0%)0/6 (0%)3/6 (50%)
Part 1 (SRD): Cohort 13: TAK-951 Dose 70/6 (0%)0/6 (0%)3/6 (50%)
Part 1 (SRD): Cohort 14: TAK-951 Dose 80/6 (0%)0/6 (0%)5/6 (83.3%)
Part 1 (SRD): Cohort 16: TAK-951 Dose 90/6 (0%)0/6 (0%)4/6 (66.7%)
Part 1 (SRD): Cohort 17: TAK-951 Dose 100/6 (0%)0/6 (0%)5/6 (83.3%)
Part 1 (SRD): Cohort 18: TAK-951 Dose 110/6 (0%)0/6 (0%)2/6 (33.3%)
Part 3 (MRD): Pooled Placebo0/8 (0%)0/8 (0%)3/8 (37.5%)
Part 3 (MRD): Cohort 10: TAK-951 Dose 1A0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 3 (MRD): Cohort 11: TAK-951 Dose 2A0/6 (0%)1/6 (16.7%)5/6 (83.3%)
Part 3 (MRD): Cohort 12: TAK-951 Dose 3A0/6 (0%)0/6 (0%)4/6 (66.7%)
Part 3 (MRD): Cohort 20: TAK-951 Dose 4A0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Ventricular tachycardiaCardiac disorders0/240/60/60/60/60/60/60/60/60/60/60/60/60/80/61/60/60/6
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPart 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4A
Dermatitis contactSkin and subcutaneous tissue disorders0/240/60/60/60/60/60/60/60/60/60/60/60/60/80/61/62/61/6
DiarrhoeaGastrointestinal disorders0/240/60/60/60/60/60/60/62/60/60/60/60/60/80/60/62/60/6
DizzinessNervous system disorders0/240/60/60/60/60/60/60/61/61/61/61/60/62/80/62/62/61/6
Dizziness posturalNervous system disorders0/240/60/61/60/60/60/61/60/61/61/60/61/60/80/62/60/60/6
HeadacheNervous system disorders0/240/60/60/60/60/60/60/60/60/60/60/60/61/80/62/62/61/6
NauseaGastrointestinal disorders0/240/60/60/60/60/60/60/60/60/60/60/60/60/80/61/62/62/6
Orthostatic hypotensionVascular disorders0/240/60/60/60/60/60/60/60/62/60/61/60/60/80/62/60/60/6
PalpitationsCardiac disorders0/240/60/60/60/60/61/61/60/61/62/61/60/60/81/61/60/61/6
Postural orthostatic tachycardia syndromeCardiac disorders0/240/60/60/60/60/60/60/60/60/61/62/60/60/80/60/60/60/6
Abdominal painGastrointestinal disorders0/240/60/60/60/60/60/60/61/60/60/60/60/60/80/60/61/60/6

Baseline characteristics

Safety Set included all randomized participants who received at least 1 dose of investigational products in each part of the study.

Age, Continuous
Age, Continuous(years)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
Mean39.4 (21 to 53)35.2 (24 to 42)40.0 (28 to 48)35.5 (26 to 41)41.8 (21 to 52)35.2 (23 to 53)34.8 (24 to 48)32.0 (24 to 43)38.7 (28 to 50)42.2 (27 to 52)34.5 (26 to 49)27.8 (20 to 37)43.0 (30 to 53)37.3 (27 to 48)35.2 (27 to 44)33.2 (23 to 39)41.3 (36 to 48)40.3 (31 to 52)37.4 (20 to 53)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
Female31012000000011110011
Male2156546666666575566117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
Hispanic or Latino60111201233233204236
Not Hispanic or Latino186555465433434462491
Unknown or Not Reported0000000000000100001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
American Indian or Alaska Native0000000000000000000
Asian1100110010000010006
Native Hawaiian or Other Pacific Islander0000000000000000000
Black or African American132222022201214210341
White92343433353354345369
More than one race1110001000000000004
Unknown or Not Reported0000010101210001108
Region of Enrollment
Region of Enrollment(Participants)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
United States2466666666666686666128
Weight
Weight(kg)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
Mean81.20 (59.8 to 106.7)78.88 (68.4 to 87.8)81.45 (64.1 to 96.2)74.10 (65.4 to 90.8)73.27 (55.4 to 88.9)76.65 (64.1 to 93.6)80.02 (60.9 to 107.1)76.27 (60.2 to 86.0)81.27 (76.2 to 86.5)78.87 (65.0 to 87.6)77.88 (66.1 to 87.5)75.17 (57.1 to 86.5)74.92 (59.8 to 88.1)78.64 (61.8 to 95.0)77.68 (65.0 to 88.8)76.35 (64.9 to 93.0)75.73 (61.5 to 93.1)83.75 (71.3 to 97.8)77.89 (55.4 to 107.1)
Height
Height(cm)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
Mean176.8 (162 to 195)174.3 (170 to 183)175.7 (170 to 184)177.8 (161 to 184)174.5 (164 to 194)177.2 (170 to 183)182.5 (174 to 193)173.8 (169 to 185)175.5 (173 to 182)174.0 (162 to 186)174.0 (158 to 179)172.5 (167 to 176)175.8 (165 to 189)175.3 (158 to 194)172.0 (162 to 181)174.7 (163 to 185)169.3 (160 to 179)175.0 (166 to 181)175.04 (158 to 195)
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Part 1 (SRD): Pooled PlaceboPart 1 (SRD): Cohort 2: TAK-951 Dose 1Part 1 (SRD): Cohort 1: TAK-951 Dose 2Part 1 (SRD): Cohort 15: TAK-951 Dose 2Part 1 (SRD): Cohort 3: TAK-951 Dose 3Part 1 (SRD): Cohort 4: TAK-951 Dose 4Part 1 (SRD): Cohort 5: TAK-951 Dose 5Part 1 (SRD): Cohort 6: TAK-951 Dose 6Part 1 (SRD): Cohort 13: TAK-951 Dose 7Part 1 (SRD): Cohort 14: TAK-951 Dose 8Part 1 (SRD): Cohort 16: TAK-951 Dose 9Part 1 (SRD): Cohort 17: TAK-951 Dose 10Part 1 (SRD): Cohort 18: TAK-951 Dose 11Part 3 (MRD): Pooled PlaceboPart 3 (MRD): Cohort 10: TAK-951 Dose 1APart 3 (MRD): Cohort 11: TAK-951 Dose 2APart 3 (MRD): Cohort 12: TAK-951 Dose 3APart 3 (MRD): Cohort 20: TAK-951 Dose 4ATotal
Mean25.99 (20.7 to 30.2)26.08 (21.2 to 30.4)26.32 (22.2 to 29.3)23.43 (19.7 to 26.8)23.90 (20.3 to 27.0)24.42 (21.5 to 29.9)23.88 (18.2 to 28.8)25.23 (20.8 to 28.7)26.43 (23.7 to 28.6)26.07 (20.7 to 28.6)25.77 (20.9 to 27.6)25.20 (18.9 to 28.0)24.25 (21.2 to 30.3)25.68 (19.9 to 29.8)26.17 (24.8 to 28.3)25.00 (21.8 to 29.0)26.32 (24.0 to 29.1)27.27 (24.8 to 30.2)25.41 (18.2 to 30.4)
08

Study locations

1 site
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment? commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Nov 2020, 19 months.

Results were first posted in Sep 2023, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Oct 5, 2022
StartActual
Mar 7, 2019
Primary completionActual
Nov 2, 2020
CompletionActual
Nov 2, 2020
Results first posted
Sep 14, 2023
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05567393
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Mar 7, 2019
Primary completion
Nov 2, 2020
Completion
Nov 2, 2020
Results posted
Sep 14, 2023
Last update
Sep 14, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-951

Start the discussion